HOUSTON, Nov. 2, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced the appointment of Brad A.
Hauser as President and Chief Executive Officer of Soliton.
He most recently served as Vice President, R&D and General
Manager for CoolSculpting at Allergan Aesthetics, an AbbVie
Company, since Allergan's April 2017
acquisition of ZELTIQ Aesthetics, Inc.
![Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. (PRNewsfoto/Soliton, Inc.) Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. (PRNewsfoto/Soliton, Inc.)](https://mma.prnewswire.com/media/871205/Soliton_Logo.jpg)
"We are extremely excited to welcome Brad Hauser as CEO. We believe this is a
monumental and pivotal appointment for the future of Soliton given
Brad's well-established reputation in the aesthetics industry.
Brad's deep expertise in aesthetics and his leadership in the
commercialization of CoolSculpting serve as a powerful endorsement
for the potential of the Soliton RAP device. As a long-standing
member of our Board, Brad has provided excellent guidance and
insight for the Soliton pipeline. We are very encouraged by the
commercialization experience and skill set he brings to the CEO
role," Walter Klemp, Soliton
Co-Founder and Executive Chairman commented.
Mr. Hauser's extensive knowledge of the aesthetic market stems
from his many years of valuable industry experience. Prior to
Allergan's acquisition of ZELTIQ, Mr. Hauser held a number of
positions for CoolSculpting including Senior Vice President of
Research and Development and Vice President of Product and Clinical
Strategy. Previously, Mr. Hauser held multiple leadership roles in
the aesthetic industry, including Executive Vice President of
Commercial Operations at Cutera, Director of Research and
Development at Medicis, and Managing Director of Product and
Clinical Marketing at Solta Medical. Mr. Hauser received his
Bachelor of Arts in Human Biology from Stanford University. He joined Soliton's Board of
Directors in June 2018.
"I am thrilled to be joining the Soliton team. We are at a very
exciting point in the organization's life cycle and are gearing up
to launch an innovative technology that has the potential to change
how the industry addresses two real patient needs: faster,
effective tattoo removal and a completely non-invasive solution for
cellulite reduction, which is currently pending FDA clearance,"
said Mr. Hauser.
As part of the organizational transition, Soliton Co-Founder and
Chief Scientific Officer Christopher
Capelli, M.D. will advance from the CEO role to Vice
Chairman of the Company's Board of Directors and continue to lead
Soliton's research and development efforts.
Dr. Capelli expressed, "The appointment of Brad as CEO is a
great benefit for Soliton, ensuring the Company is well positioned
to execute its commercial strategies in the aesthetic space. His
years of leadership have earned the respect of the entire
aesthetics community, giving us the added ability to attract top
talent for our organization as we grow the commercial side of our
business. With Brad leading the commercialization effort, I can
remain focused on the continued development of the Soliton
technology platform."
------------------------
Join our more than 200K
subscribers here to follow the Company:
https://soly-investors.com
------------------------
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer
Center. The Company's first FDA cleared commercial product will use
rapid pulses of acoustic shockwaves as an accessory to lasers for
the removal of unwanted tattoos. The Company is based in
Houston, Texas, and is actively
engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the
market. The Company believes this "Soliton" method has the
potential to lower tattoo removal costs for patients, while
increasing profitability to practitioners, compared to current
laser removal methods. Soliton has filed a 510(k) application
with the FDA for clearance of its RAP device to improve the
appearance of cellulite and is investigating potential additional
capabilities of the RAP technology. The device is currently cleared
in the United States only for use
in tattoo removal and is not yet cleared for use to address
cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, our ability to hire additional
commercial staff and launch our products into the aesthetics
market. These statements relate to future events, future
expectations, plans and prospects. Although Soliton believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, actual results or outcomes may
prove to be materially different from the expectations expressed or
implied by such forward-looking statements. Soliton has attempted
to identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' "would," ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
in our filings with the Securities and Exchange Commission ("SEC"),
including under the heading " Risk Factors" in the Form 10-K for
year ended December 31, 2019 filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-appoints-aesthetic-executive-veteran-brad-hauser-as-president-and-chief-executive-officer-in-preparation-for-commercial-launch-301164150.html
SOURCE Soliton, Inc.